Mylan Laboratories said late Wednesday that it will license nebivolol, an experimental blood pressure drug, to Forest Laboratories. In return for marketing rights for nebivolol in the U.S. and Canada, Forest will make an upfront payment of $75 million, and will pay Mylan royalties based on future sales. Forest also will assume all development of the drug, and will pay for sales and marketing expenses.

The Street

(http://www.thestreet.com/_googlen/stocks/biotech/10261452.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA)